title: Why a Combination of WP 631 and Epo B is an Improvement on the Drugs Singly - Involvement in the Cell Cycle and Mitotic Slippage.
abstract: Our previous studies clearly demonstrated that a combination of WP 631 and Epo B has higher activity against ovarian cancer cells than either of these compounds used separately. In order to fully understand the exact mechanism of action in combination, we assessed effects on the cell cycle of SKOV-3 cells. We evaluated three control points essential for WP 631 and Epo B action to determine which cell cycle-regulating proteins (CDK1/cyclin B complex, EpCAM or HMGB1) mediate activity. The effects of the drug on the cell cycle were measured based on the nuclear DNA content using flow cytometry. Expression of cell cycle-regulating genes was analyzed using real-time PCR. It was discovered that WP 631, at the tested concentration, did not affect the SKOV-3 cell cycle. Epo B caused significant G2/M arrest, whereas the drug combination induced stronger apoptosis and lower mitotic arrest than Epo B alone. This is very important information from the point of view of the fight against cancer, as, while mitotic arrest in Epo B-treated cells could be overcame after DNA damage repair, apoptosis which occurs after mitotic slippage in combination-treated cells is irreversible. It clearly explains the higher activity of the drug combination in comparison to Epo B alone. Epo B acts via the CDK1/cyclin B complex and has the ability to inhibit CDK1, which may be a promising strategy for ovarian cancer treatment in the future. The drug combination diminishes EpCAM and HMGB1 expression to a greater degree than either WP 631 and Epo B alone. Owing to the fact that the high expression of these two proteins is a poor prognostic factor for ovarian cancer, a decrease in their expression, observed in our studies, may result in improved efficacy of cancer therapy. The presented findings show that the combination of WP 631 and Epo B is a better therapeutic option than either of these drugs alone.
authors.affiliation: Department of Medical Biophysics, Institute of Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska, Lodz, Poland E-mail : barbuk@biol.uni.lodz.pl.
authors.forename: Barbara
authors.initials: B
authors.lastname: Bukowska
authors.forename: Aneta
authors.initials: A
authors.lastname: Rogalska
authors.forename: Ewa
authors.initials: E
authors.lastname: Forma
authors.forename: Magdalena
authors.initials: M
authors.lastname: Brys
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Marczak
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects*; D018797:Cell Cycle Proteins / Q000235:genetics; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D034261:Epothilones / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008938:Mitosis / Q000187:drug effects*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D060888:Real-Time Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D034261:Epothilones; C104426:WP 631; C093788:epothilone B; D003630:Daunorubicin